(Q24234938)

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Long-term prevention of post-operative recurrence in Crohn's disease cannot be affected by mesalazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Application of a stopping rule based on total treatment failures: the postoperative Crohn's disease trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Surgical therapy for ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Quality of Life Improves Within 30 Days of Surgery for Crohn’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Management of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Methotrexate for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Probiotics for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Corticosteroids for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Assessment of long-term quality of life after laparoscopic and open surgery for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Recurrence of Crohn's disease after resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

1 reference

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008414.PUB2

7 January 2021

10.1002/14651858.CD008414.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

21249709

1 reference

Consolidated OpenCitations Corpus – April 2017